My medico space

The global medical community has reached a dangerous crossroads: Antimicrobial Resistance (AMR).  For decades, overuse and misuse of standard antibiotics have allowed bacteria to evolve into "superbugs" capable of resisting our most potent reserve drugs.  As traditional pipelines dried up, clinicians faced a daunting question: What happens when the antibiotics run out? India has provided an answer. Developed by Mumbai-based pharmaceutical leader Wockhardt, Zaynich™ (a combination of cefepime and zidebactam) has secured regulatory approval from both India’s CDSCO and the US FDA. This milestone marks the first time a New Chemical Entity (NCE) discovered and developed entirely in India has earned US FDA approval, signaling a historic transition from manufacturing generic medicines to leading frontline global drug discovery. What is Zaynich™? Zaynich™ is an intravenous, novel combination antibiotic designed to combat highly resistant, hard-to-treat Gram-negative bacterial infecti...

                                                             SUPERBUG These are the microbial strains that have become resistant to the drugs used to treat them. Nowadays, as per the availability of internet and several medical terms and chemical names used commonly has somehow made common man aware of certain drugs which were not easily available or known. Examples of Superbug:- (Ref. PubMed) MRSA- Methicillin resistant Staphylococcus aureus- these bacteria don't respond to methicillin and related antibiotics. Acinetobacter baumannii- resistant to carbapenem Pseudomonas aeruginosa- resistant to carbapenem Enterobacteriaceae- resistant to carbapenem Neisseria gonorrhoeae- Cephalosporin and fluoroquinolone resistant Enterococcus faecium- vancomycin resistant Non-typhoidal salmonella- Fluoroquinolones resistant Helicobacter pylori- Clar...